Prisoners who are able to get hepatitis C antivirals while they are still incarcerated can be lost to treatment when they are freed. A community linkage program in the Bronx, NY is having success keeping the patients on their drug regimens.
After a newspaper report found that less than 10 of Tennessee's thousands of HCV-positive prisoners were receiving treatment, two inmates sued the state. Now, prison officials are seeking a bit more help in battling the disease.
An investigational combination drug that targets all major genotypes of hepatitis C had a high success rate in a clinical trial of patients with severe chronic kidney disease, curing 98% of those who received 12 weeks of treatment.
Results from three clinical trials of an investigational drug being developed by AbbVie to treat all major genotypes of the hepatitis C virus show high cure rates at or above 95% among patients tested.